Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ RAB3IP Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA544020
Description
Peptide sequence: SPDLLGVYES GTQEQTTSPS VIYRPHPSAL SSVPIQANAL DVSELPTQPV Sequence homology: Cow: 93%; Dog: 100%; Guinea Pig: 93%; Horse: 91%; Human: 100%; Mouse: 79%; Rabbit: 92%; Rat: 93%.
Guanine nucleotide exchange factor (GEF) which may activate RAB8A and RAB8B. Promotes the exchange of GDP to GTP, converting inactive GDP-bound Rab proteins into their active GTP-bound form. Mediates the release of GDP from RAB8A and RAB8B but not from RAB3A or RAB5. Modulates actin organization and promotes polarized transport of RAB8A-specific vesicles to the cell surface. Together with RAB11A, RAB8A, the exocyst complex, PARD3, PRKCI, ANXA2, CDC42 and DNMBP promotes transcytosis of PODXL to the apical membrane initiation sites (AMIS), apical surface formation and lumenogenesis.
Specifications
RAB3IP | |
Polyclonal | |
Unconjugated | |
RAB3IP | |
B230311A06; gene trap PAT 12; Gtpat12; MGC137223 protein; RAB3A interacting protein; RAB3A interacting protein (rabin3); rab-3A-interacting protein; RAB3A-interacting protein; RAB3IP; rab3ip {ECO:0000250; rabin 3; Rabin3; rabin-3; RABIN8; SSX2 interacting protein; SSX2-interacting protein; UniProtKB:Q96QF0} | |
Rabbit | |
Affinity Chromatography | |
RUO | |
117177, 216363 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Liquid |
Immunohistochemistry, Western Blot, Immunocytochemistry | |
0.5 mg/mL | |
PBS with 2% sucrose and 0.09% sodium azide | |
Q68EF0, Q96QF0 | |
RAB3IP | |
Synthetic peptide directed towards the N-terminal of human RAB3IP (aa 35-84). | |
100 μL | |
Primary | |
Human, Mouse | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction